InterAx Biotech unveils breakthrough drug candidates by identifying unique modes of drug action on cell signalling. This enables design of superior drugs for multiple indications. Such novel cellular signaling modes of action were uncovered by the company's most advanced Artificial Intelligence platform - facilitating design of efficacious orally available drugs for diabetes, obesity, and immuno oncology. The InterAx Biotech approach, together with the latest results on the immune oncology program, will be presented as invited speakers at the 3rd Annual #GPCR s-Targeted Drug Discovery Summit to be held on March 5-7 in Boston, MA 🇺🇸. 👉🏼 https://lnkd.in/edm2nE2G Christopher Prior, CEO Aurélien Rizk, CSO #drugdiscovery #biotechnology #innovation
InterAx Biotech’s Post
More Relevant Posts
-
M-Pharm Pharmaceutical Biotechnology at Sanijivini Collage of Pharmaceutical Education and Research Autonomous
🎉Ecstatic to unveil our latest breakthrough! 'The Tumor Microenvironment: Shaping Cancer Progression and Treatment Responses' in the esteemed Taylor and Francis Journal of Chemotherapy. This achievement signifies a substantial advancement in our comprehension of cancer and its therapeutic approaches. I extend my sincere congratulations to our esteemed guide, Dr. Sharav Desai and Dr. Vipul P. Patel, for their invaluable guidance, and profound appreciation to our diligent team members, Kirti Thombare and Sandip Nagare, for their unwavering dedication to this pursuit at Sanjivani Group of Institutes, specifically SRES' Sanjivani College of Pharmaceutical Education and Research,Kopargaon. Dive into our paper with the DOI: https://lnkd.in/dsbQeGgJ #cancerresearch #tumormicroenvironment #cytokines #chemotherapy #immunotherapy
To view or add a comment, sign in
-
The multiple myeloma treatment landscape is rapidly evolving with groundbreaking advancements! In 2023, there were around 75,000 incidence cases in the 7MM, predominantly affecting those aged 65+. Key therapies include Proteasome Inhibitors like VELCADE, KYPROLIS, and NINLARO; IMiDs such as THALOMID, REVLIMID, and POMALYST; Monoclonal Antibodies like DARZALEX and SARCLISA; CAR-T Cell Therapies such as ABECMA and CARVYKTI; and Bispecific Antibodies like TALVEY. The market, valued at approximately $21.3B, is driven by innovators like GSK, Bristol Myers Squibb, AbbVie, and Janssen Inc.. Learn more about the latest breakthroughs and market dynamics here: https://lnkd.in/gQmc-CXc #MultipleMyeloma #CancerResearch #PharmaInnovation #Healthcare #Biotech #MedicalAdvancements
To view or add a comment, sign in
-
Interested in KRAS? Tempus is presenting Beyond G12: Comprehensive RAS Biomarker Strategy and Clinical Development at RAS-Targeted Drug Development Summit 2024 KRAS G12C is only the first druggable alteration in RAS genes. Tempus’ multimodal, de-identified data and certain assays can help identify a broad set of biomarkers in responsive patients including KRAS, HRAS, and NRAS amplifications, over-expression, and mutations, in addition to tumor immune microenvironment factors that may influence response to RAS neoantigen vaccines, revealing critical insights for targeted therapy development. Gain perspective on the significance of RAS alteration patterns to outcomes to standard of care and their potential to guide precision oncology, enhancing treatment efficacy and patient outcomes. Not attending? Let's connect! #PrecisionOncology #ClinicalDevelopment #BiomarkerStrategy #RAS #KRAS #NRAS #G12C #G12D
To view or add a comment, sign in
-
#CAR_T_Cell_Therapy Market Size, Trends, Growth Rate, Analysis Report Upto 2032 >> https://lnkd.in/dvunEJHN #CAR T cell therapy is an advanced form of #immunotherapy that involves modifying a #patient’s T cells to target and attack #cancer cells. This therapy uses genetically engineered T #cells with chimeric antigen #receptors (CARs) that bind to cancer cell #antigens. These therapies provide a highly targeted and personalized #treatment approach by enhancing the T cells' ability to recognize and #destroy malignant cells. Gilead Sciences Novartis Bristol-Myers Squibb Pharma Company Janssen Global Services LLC Caribou Biosciences JW Therapeutics 药明巨诺 Cartesian Therapeutics Aurora BioPharma #celltherapy #immunotherapy #cancercells #therapies #treatment #research #bloodcancers #leukemia
To view or add a comment, sign in
-
📢 Register your place on our upcoming webinar! Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology. 👉 Review key cytokines involved in inflammatory diseases 👉 Examine case studies highlighting the application of various cell-based assay formats to assess the mechanism of action of antibodies targeting existing & emerging cytokine targets in inflammatory disease 👉 Understand optimal assay formats for assessing antibody specificity vs successful detection of neutralizing antibodies in cell-based assays Interested? Sign up here: https://bit.ly/3vpPZoi #Webinar #Assays #Therapeutics #Cytokines
To view or add a comment, sign in
-
If you focus on oncology research and need data analysis for: 🔵 Drug target identification and validation 🔵 Biomarker identification for mechanism of action or drug efficacy 🔵 Biomarker prediction for patient stratification We can help! ⬇️Check the link in our comment below to discover our oncology services!⬇️
To view or add a comment, sign in
-
Interested in KRAS? Tempus is presenting Beyond G12: Comprehensive RAS Biomarker Strategy and Clinical Development at RAS-Targeted Drug Development Summit 2024 KRAS G12C is only the first druggable alteration in RAS genes. Tempus’ multimodal, de-identified data and certain assays can help identify a broad set of biomarkers in responsive patients including KRAS, HRAS, and NRAS amplifications, over-expression, and mutations, in addition to tumor immune microenvironment factors that may influence response to RAS neoantigen vaccines, revealing critical insights for targeted therapy development. Gain perspective on the significance of RAS alteration patterns to outcomes to standard of care and their potential to guide precision oncology, enhancing treatment efficacy and patient outcomes. Not attending? Let's connect! #PrecisionOncology #ClinicalDevelopment #BiomarkerStrategy #RAS #KRAS #NRAS #G12C
To view or add a comment, sign in
-
To effectively optimize drug dosage in early phase oncology, sponsors should plan for added operational load from increased data collection, assessments and strict turnaround time for assay work. In this Contract Pharma article, IQVIA Biotech’s VP of Immuno-Oncology & CAGT Erin Finot, MS, MBA discusses operational considerations for clinical trial stakeholders. Read the article to learn more. https://bit.ly/3UdblQ0 #IQVIABiotech #clinicaltrials #oncology
Cell and Gene R&D in Cancer Care: Increasing Patient Access
iqvia.com
To view or add a comment, sign in
-
The rapid advancement of targeted therapeutics has significantly improved treatment precision and efficacy in oncology and metabolic disorders. This article integrates key developments in four areas: highly selective PPAR modulators for metabolic and inflammatory diseases; CRISPR-engineered T-cell receptor therapies targeting the KRAS G12D mutation in cancer; strategies to enhance antitumor immunity through glutamine metabolism modulation in the tumor microenvironment; and a novel system for analyzing coformulated biologics. These innovations highlight the integration of metabolic modulation, immune system engineering, and advanced biologic formulation, paving the way for more effective and personalized therapeutic approaches. #drugdevelopment #science #medicinalchemistry #drugdiscovery #medicine #drugspharmaceuticals #oncology #drug - https://lnkd.in/gpEh-snJ
Advancements in Targeted Therapeutics: Integrating Metabolic Modulation, Immune Engineering, and Biologic Formulation Technologies
pubs.acs.org
To view or add a comment, sign in
1,710 followers
Head of Advanced Studies at Clinical Trials Center Zurich
8moCool pic!